The average one-year price target for Aptevo Therapeutics (NASDAQ:APVO) has been revised to 18.36 / share. This is an increase of 24.14% from the prior estimate of 14.79 dated July 5, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 18.18 to a high of 18.90 / share. The average price target represents an increase of 1,665.38% from the latest reported closing price of 1.04 / share.
What is the Fund Sentiment?
There are 42 funds or institutions reporting positions in Aptevo Therapeutics. This is a decrease of 3 owner(s) or 6.67% in the last quarter. Average portfolio weight of all funds dedicated to APVO is 0.00%, a decrease of 25.52%. Total shares owned by institutions decreased in the last three months by 7.32% to 909K shares.
What are Other Shareholders Doing?
Cantor Fitzgerald, L. P. holds 219K shares representing 2.90% ownership of the company. In it's prior filing, the firm reported owning 215K shares, representing an increase of 1.60%. The firm decreased its portfolio allocation in APVO by 32.80% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 158K shares representing 2.10% ownership of the company. No change in the last quarter.
Schonfeld Strategic Advisors holds 144K shares representing 1.91% ownership of the company. In it's prior filing, the firm reported owning 142K shares, representing an increase of 1.18%. The firm increased its portfolio allocation in APVO by 2.12% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 69K shares representing 0.92% ownership of the company. In it's prior filing, the firm reported owning 79K shares, representing a decrease of 13.91%. The firm decreased its portfolio allocation in APVO by 27.05% over the last quarter.
Renaissance Technologies holds 55K shares representing 0.73% ownership of the company. In it's prior filing, the firm reported owning 65K shares, representing a decrease of 19.10%. The firm decreased its portfolio allocation in APVO by 28.53% over the last quarter.
Aptevo Therapeutics Background Information
(This description is provided by the company.)
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The Company's lead clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed based on the Company's versatile and robust ADAPTIR™ modular protein technology platform. The ADAPTIR™ platform is capable of generating highly differentiated bispecific antibodies with unique mechanisms of action for the treatment of different types of cancer.
Additional reading:
- Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML Phase 2 Trials in Relapsed/Refractory and Frontline Settings Planned, APVO436 to be administered in Combination with Emerging
- Form of Securities Purchase Agreement
- Form of Common Warrant
- Form of Pre-Funded Warrant
- APTEVO THERAPEUTICS REPORTS 1Q23 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company Achieves Multiple Clinical and Preclinical Milestones and Raises $9.7 Million in Non-Dilutive Funding, Eliminates Balance Sheet Debt Introduces Novel Compound APV
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
